DHFB
JAZZ icon

Dixon Hubard Feinour & Brown’s Jazz Pharmaceuticals JAZZ Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,450
Closed -$213K – 193
2014
Q2 		$213K Sell
1,450
-600
-29% -$83.2K 0.07% 179
2014
Q1 		$284K Hold
2,050
– – 0.1% 145
2013
Q4 		$259K Buy
+2,050
New +$212K 0.1% 143

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dixon Hubard Feinour & Brown's JAZZ Position: Q3 2014 in Review

Dixon Hubard Feinour & Brown sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2014, closing a stake of 1,450 shares — an estimated $213K sold.

Dixon Hubard Feinour & Brown first reported a position in JAZZ in Q4 2013 and held it in 3 quarters. The position peaked at $284K in Q1 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • Dixon Hubard Feinour & Brown reported no remaining Jazz Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Dixon Hubard Feinour & Brown sold 1,450 Jazz Pharmaceuticals shares in Q3 2014, an estimated $213K.
  • Dixon Hubard Feinour & Brown first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Dixon Hubard Feinour & Brown's Jazz Pharmaceuticals position peaked at $284K in Q1 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q3 2014, filed 13 Nov 2014.